We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.12 | -8.63309352518 | 1.39 | 1.4397 | 1.2 | 41362 | 1.2932135 | CS |
4 | -0.31 | -19.6202531646 | 1.58 | 1.7203 | 1.2 | 80212 | 1.46938045 | CS |
12 | -0.53 | -29.4444444444 | 1.8 | 2.2 | 1.2 | 94968 | 1.7566281 | CS |
26 | -1.17 | -47.9508196721 | 2.44 | 3.32 | 1.2 | 75310 | 2.03553403 | CS |
52 | -6.08 | -82.7210884354 | 7.35 | 8.7 | 1.2 | 92509 | 4.45552446 | CS |
156 | -75.23 | -98.339869281 | 76.5 | 87.6 | 1.2 | 444175 | 31.33904972 | CS |
260 | -27.68 | -95.6131260794 | 28.95 | 138.7875 | 1.2 | 782377 | 64.36343833 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions